AVEO retains all rights to the development and commercialization of ficlatuzumab.

and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical production of ficlatuzumab, AVEO’s novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-little cell lung cancers . Boehringer Ingelheim shall produce ficlatuzumab for clinical trials at its biopharmaceutical site in Fremont, USA. AVEO retains all rights to the development and commercialization of ficlatuzumab.Lenalidomide, at a dose of 5 mg daily, was began on day 130 after transplantation; the dosage was subsequently reduced to 5 mg weekly due to gastrointestinal toxic effects twice. Clinical Response The monoclonal IgA concentration and the full total serum IgA concentration started to decline after transplantation and declined further after CTL019 infusion . The nadir IgA concentration was below the limit of quantitation . On day time 100, a bone marrow biopsy showed 1 to 2 percent overall cellularity and no plasma cells . Flow-cytometric tests and IGH deep sequencing of the bone marrow sample attained on time 100 for minimal residual disease were unfavorable; IGH deep sequencing indicated a frequency of less than 1 neoplastic plasma cell in 3.